Reduce Negative Moods and Depression in Healthy Individuals and Patients with Mood Disorders with Psychedelic Drugs
By John M. de Castro, Ph.D.
“the therapeutic use of psychedelic drugs in psychotherapeutic settings represents a promising and integrative treatment with enduring effects for mental health patients.” – Genis Oña
Psychedelic substances such as peyote, mescaline, LSD, Bufotoxin, ayahuasca and psilocybin have been used almost since the beginning of recorded history to alter consciousness and produce spiritually meaningful experiences. People find these experiences extremely pleasant. eye opening, and even transformative. They often report that the experiences changed them forever. Psychedelics have also been found to be clinically useful as they markedly improve mood, increase energy and enthusiasm and greatly improve clinical depression.
The research on the effectiveness of psychedelic drugs on mood and clinical depression is accumulating. So, it makes sense to step back and summarize what has been learned. In today’s Research News article “Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.” (See summary below or view the full text of the study at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826317/ ) Galvão-Coelho and colleagues review, summarize, and perform a meta-analysis of the published research studies of the effectiveness of psychedelic drugs in improving mood and reducing depression with healthy individuals and patients with mood disorders.
They identified 12 published randomized controlled trials; 8 used psilocybin, 3 LSD, and 1 ayahuasca. They report that the research found that psychedelic treatment produced significant reductions in negative moods and depression in both healthy participants and in patients with mood disorders. In mood disorder patients the improvements were still significant 2 months after treatment. It should be recognized that the application of the psychedelics in these studies occur in highly structured controlled environments. This produces few if any troubling side effects with the exception of occasional slight anxiety. The safety of these drugs in uncontrolled non-clinical settings are not known.
The published research is clear that psychedelic drugs are effective in improving mood and reducing depression in both healthy individuals and those with mood disorders. Mood disorders including depression are by far the most common psychological problems in humans. The research is suggesting that controlled administration of psychedelic drugs is a safe and effective treatment relieving the suffering.
So, reduce negative moods and depression in healthy individuals and patients with mood disorders with psychedelic drugs.
“People who had recently used psychedelics such as psilocybin report a sustained improvement in mood and feeling closer to others after the high has worn off.” – Bill Hathaway
CMCS – Center for Mindfulness and Contemplative Studies
This and other Contemplative Studies posts are also available on Google+ https://plus.google.com/106784388191201299496/posts and on Twitter @MindfulResearch
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021). Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 238(2), 341–354. https://doi.org/10.1007/s00213-020-05719-1
Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option.
We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately).
Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2–7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms.
Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.